Molecular biology and novel therapeutics for IDH mutant gliomas: The new era of IDH inhibitors

Biochim Biophys Acta Rev Cancer. 2024 Apr 21:189102. doi: 10.1016/j.bbcan.2024.189102. Online ahead of print.ABSTRACTGliomas with Isocitrate dehydrogenase (IDH) mutation represent a discrete category of primary brain tumors with distinct and unique characteristics, behaviors, and clinical disease outcomes. IDH mutations lead to aberrant high-level production of the oncometabolite D-2-hydroxyglutarate (D-2HG), which act as a competitive inhibitor of enzymes regulating epigenetics, signaling pathways, metabolism, and various other processes. This review summarizes the significance of IDH mutations, resulting upregulation of D-2HG and the associated molecular pathways in gliomagenesis. With the recent finding of clinically effective IDH inhibitors in these gliomas, this article offers a comprehensive overview of the new era of innovative therapeutic approaches based on mechanistic rationales, encompassing both completed and ongoing clinical trials targeting gliomas with IDH mutations.PMID:38653436 | DOI:10.1016/j.bbcan.2024.189102
Source: Biochimica et Biophysica Acta - Category: Biochemistry Authors: Source Type: research